Camlin Fine Sciences is a specialty-chemical company built on a single, recurring idea: own the molecule from raw material to finished solution, then move closer to the customer’s recipe. It began in the 1990s as an antioxidant unit of an Indian stationery company, but the business transformed in 2012 when it bought an Italian plant that made Hydroquinone and Catechol - the two building blocks of its entire product chain - giving it captive control of inputs that rivals have to buy. Over the last three years, the company has deliberately shifted from selling single-molecule “straight” chemicals toward custom-formulated “blends” - mixtures tailored to a specific customer’s shelf-life or performance problem - which makes the relationship stickier and the business harder to undercut on price.
Business segments
Three engines built on the same diphenol backbone - a shelf-life solutions business that is the group’s commercial heart, an aroma-ingredients plant that turns captive catechol into vanillin, and a performance-chemicals unit that supplies the industrial world while feeding the other two.
1. Shelf-life solutions and blends: the group’s commercial engine
This is where the company makes most of its money - not by selling commodity antioxidant molecules, but by formulating over 200 custom blends that keep food, pet food and feed fresh longer, and those blends now account for three-quarters of the segment.
- Custom recipes, not just molecules - the company takes its own antioxidant straights (TBHQ, BHA and Ascorbyl Palmitate) and combines them with natural extracts like rosemary, green tea and mixed tocopherols into more than 200 tailored formulations, each designed for a specific customer’s oil stability, feed preservation or clean-label requirement. That turns a commodity input into a high-value solution the customer is reluctant to switch.
- Dominant in the base molecules - CFS holds over 50% of the global market for TBHQ and BHA, the single-molecule antioxidants that are the raw material for its own blends and that it still sells as straights to industries from edible oils to biodiesel. When straight-molecule prices come under pressure from local competitors, the company deliberately channels that volume into its own blends rather than fighting on price.
- Pet food is the biggest plate - in FY2024-25, pet food contributed more than 55% of the segment’s revenue, with North America leading the growth, reflecting a customer base of large multinationals and regional manufacturers that need antioxidants to stop fats going rancid in dry and wet pet food.
- A lab on every continent - six application laboratories in Italy, India, the US, Mexico, Belgium and Brazil develop custom blends, run stability studies and provide technical support directly to customers, which is how a chemical company builds relationships that last. Manufacturing for blends happens at facilities in India, Brazil, Mexico and Belgium, plus a contract arrangement in the US.
- Moving into how food feels - the newest products are emulsifier-based ingredients that improve texture, mouthfeel and process efficiency for bakeries, chocolate makers and confectioners, sold under the Ezential brand alongside the natural-antioxidant NaSure range.
2. Aroma ingredients: vanillin from the group’s own catechol
CFS is the only India-based producer of vanillin and ethyl vanillin, made in a fully integrated plant where the raw material catechol comes from the group’s own diphenol facility - and anti-dumping duties on Chinese rivals are reshaping the market in its favour.
- Ethyl vanillin is the pivot - in early 2026, the company stopped methyl vanillin production and converted the plant to ethyl vanillin, which is three times more potent and commands a higher price. Orders on hand for the next quarter were roughly 300 metric tons, with a production campaign of about 600 metric tons planned, and average realisations rose from below $11 to above $12.50 per kilogram.
- Tariffs are a tailwind - Chinese producers have used predatory pricing and dumping, which led the US and European Union to levy anti-dumping duties on Chinese vanillin, benefiting CFS as the only non-Chinese manufacturer at scale. The company still faces a 15% tariff on its own vanillin in those markets, and has managed inventory timing to reduce the impact.
- The China JV is being wound down - CFS’s former vanillin plant in China, operated through a joint venture, has been shut since February 2021 due to a legal dispute over intellectual property, and the board approved its liquidation in May 2025, removing a distraction and a source of legal risk.
3. Performance chemicals: the diphenol backbone and its industrial derivatives
This engine makes the two diphenols - hydroquinone and catechol - that feed the group’s own vanillin and antioxidant businesses, while also selling derivatives into petrochemicals, agrochemicals and pharmaceuticals, though the manufacturing model is being restructured under cost pressure.
- Two molecules, one reaction - phenol is converted into hydroquinone and catechol as joint products in a roughly 40-45% to 55% ratio, meaning you cannot make one without the other. That joint-production reality is why the group’s vertical integration matters: catechol goes into vanillin, hydroquinone derivatives go into antioxidants like TBHQ, and the surplus is sold externally.
- Dahej replaced Italy - the greenfield diphenol plant at Dahej, commissioned in 2020, was built to produce at a much lower cost than the legacy Italian facility, using a lean workforce of around 70 people and a heat-conservation system that cuts raw-material consumption and carbon footprint. Capacity was expanded from 10,000 to 15,000 tonnes per year through a de-bottlenecking exercise completed in 2022, funded entirely from internal cash.
- The Italian subsidiary is in liquidation - the Ravenna diphenol facility ceased operations in August 2023 after a steep decline in prices and demand, was deemed economically unviable, and judicial liquidation proceedings were initiated for CFS Europe S.p.A. in March 2026. The blending business in Italy continues separately.
- Even Dahej is under review - by early 2026, with phenol raw-material costs having jumped from INR 85 to INR 150 per kilogram and catechol in global oversupply selling below production cost, the company cut diphenol manufacturing at Dahej to reduce cash burn, choosing instead to import hydroquinone from China and draw down existing catechol stock that covers 8-9 months of vanillin production.
- Derivatives reach industrial customers - the downstream portfolio includes MEHQ, HQEE, Chloranil and Guaiacol, sold into polymers, agrochemicals, pharmaceuticals and printing inks, and the company holds a long-term preferred supply agreement with Lockheed Martin for a catechol derivative used in flow-battery energy storage.
Group structure and partners
A global network of manufacturing and sales subsidiaries across Europe, the Americas and Asia, with two major operations now in liquidation and a fresh acquisition in France adding natural-ingredient technology.
- European footprint in transition - the Italian diphenol subsidiary CFS Europe is in judicial liquidation, while the recently acquired Belgian company Vitafor (bought for €1 in 2024) manufactures feed ingredients and nutritional products near the Port of Antwerp, contributing ₹8,488 lakh in revenue in FY2024-25. Vinpai, the French functional-ingredients company listed on Euronext Growth, became an 83.82% subsidiary in January 2026, bringing over 3,500 formulas based on algae, plants and minerals and serving customers in more than 36 countries.
- Americas built through acquisition - Dresen Quimica in Mexico, now wholly owned through CFS Mexico after a merger in 2025, manufactures and distributes specialty chemical solutions across North, Central and South America with its own sales force and subsidiaries in Peru, Colombia, Guatemala and the Dominican Republic. CFS do Brasil operates a 6,000-tonne blending plant and handles distribution of bulk antioxidants and vanillin in South America.
- Asia anchored by India and a discontinued China JV - the vanillin joint venture in Ningbo, China, is in liquidation with retrospective effect from December 31, 2024, while the 80%-owned AlgalR NutraPharms in India produces algal Omega-3 fatty acids under the BioSus brand using proprietary fermentation technology. Chemolutions Chemicals, a 94% subsidiary, does contract manufacturing for CFS at Tarapur.
- One strategic customer of note - the long-term preferred supply agreement with Lockheed Martin for a catechol derivative used in flow batteries is a small but distinctive validation of the group’s chemistry capabilities in advanced energy storage.